These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
573 related articles for article (PubMed ID: 19854204)
1. DARPin-assisted crystallography of the CC2-LZ domain of NEMO reveals a coupling between dimerization and ubiquitin binding. Grubisha O; Kaminska M; Duquerroy S; Fontan E; Cordier F; Haouz A; Raynal B; Chiaravalli J; Delepierre M; Israël A; Véron M; Agou F J Mol Biol; 2010 Jan; 395(1):89-104. PubMed ID: 19854204 [TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the NEMO ubiquitin-binding domain in complex with Lys 63-linked di-ubiquitin. Yoshikawa A; Sato Y; Yamashita M; Mimura H; Yamagata A; Fukai S FEBS Lett; 2009 Oct; 583(20):3317-22. PubMed ID: 19766637 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of NF-kappaB activation with designed ankyrin-repeat proteins targeting the ubiquitin-binding/oligomerization domain of NEMO. Wyler E; Kaminska M; Coïc YM; Baleux F; Véron M; Agou F Protein Sci; 2007 Sep; 16(9):2013-22. PubMed ID: 17766391 [TBL] [Abstract][Full Text] [Related]
4. Direct inhibition of NF-κB activation by peptide targeting the NOA ubiquitin binding domain of NEMO. Chiaravalli J; Fontan E; Fsihi H; Coic YM; Baleux F; Véron M; Agou F Biochem Pharmacol; 2011 Nov; 82(9):1163-74. PubMed ID: 21803029 [TBL] [Abstract][Full Text] [Related]
5. Two-sided ubiquitin binding of NF-κB essential modulator (NEMO) zinc finger unveiled by a mutation associated with anhidrotic ectodermal dysplasia with immunodeficiency syndrome. Ngadjeua F; Chiaravalli J; Traincard F; Raynal B; Fontan E; Agou F J Biol Chem; 2013 Nov; 288(47):33722-33737. PubMed ID: 24100029 [TBL] [Abstract][Full Text] [Related]
6. Solution structure of NEMO zinc finger and impact of an anhidrotic ectodermal dysplasia with immunodeficiency-related point mutation. Cordier F; Vinolo E; Véron M; Delepierre M; Agou F J Mol Biol; 2008 Apr; 377(5):1419-32. PubMed ID: 18313693 [TBL] [Abstract][Full Text] [Related]
7. Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Rushe M; Silvian L; Bixler S; Chen LL; Cheung A; Bowes S; Cuervo H; Berkowitz S; Zheng T; Guckian K; Pellegrini M; Lugovskoy A Structure; 2008 May; 16(5):798-808. PubMed ID: 18462684 [TBL] [Abstract][Full Text] [Related]
9. Disulfide-mediated stabilization of the IκB kinase binding domain of NF-κB essential modulator (NEMO). Zhou L; Yeo AT; Ballarano C; Weber U; Allen KN; Gilmore TD; Whitty A Biochemistry; 2014 Dec; 53(50):7929-44. PubMed ID: 25400026 [TBL] [Abstract][Full Text] [Related]
10. Mechanism underlying IκB kinase activation mediated by the linear ubiquitin chain assembly complex. Fujita H; Rahighi S; Akita M; Kato R; Sasaki Y; Wakatsuki S; Iwai K Mol Cell Biol; 2014 Apr; 34(7):1322-35. PubMed ID: 24469399 [TBL] [Abstract][Full Text] [Related]
11. New mechanism of X-linked anhidrotic ectodermal dysplasia with immunodeficiency: impairment of ubiquitin binding despite normal folding of NEMO protein. Hubeau M; Ngadjeua F; Puel A; Israel L; Feinberg J; Chrabieh M; Belani K; Bodemer C; Fabre I; Plebani A; Boisson-Dupuis S; Picard C; Fischer A; Israel A; Abel L; Veron M; Casanova JL; Agou F; Bustamante J Blood; 2011 Jul; 118(4):926-35. PubMed ID: 21622647 [TBL] [Abstract][Full Text] [Related]
12. The trimerization domain of NEMO is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains. Agou F; Traincard F; Vinolo E; Courtois G; Yamaoka S; Israël A; Véron M J Biol Chem; 2004 Jul; 279(27):27861-9. PubMed ID: 15107419 [TBL] [Abstract][Full Text] [Related]
13. NEMO specifically recognizes K63-linked poly-ubiquitin chains through a new bipartite ubiquitin-binding domain. Laplantine E; Fontan E; Chiaravalli J; Lopez T; Lakisic G; Véron M; Agou F; Israël A EMBO J; 2009 Oct; 28(19):2885-95. PubMed ID: 19763089 [TBL] [Abstract][Full Text] [Related]
14. Structural basis for recognition of diubiquitins by NEMO. Lo YC; Lin SC; Rospigliosi CC; Conze DB; Wu CJ; Ashwell JD; Eliezer D; Wu H Mol Cell; 2009 Mar; 33(5):602-15. PubMed ID: 19185524 [TBL] [Abstract][Full Text] [Related]
15. NEMO oligomerization and its ubiquitin-binding properties. Ivins FJ; Montgomery MG; Smith SJ; Morris-Davies AC; Taylor IA; Rittinger K Biochem J; 2009 Jun; 421(2):243-51. PubMed ID: 19422324 [TBL] [Abstract][Full Text] [Related]
16. Dimerization of the I kappa B kinase-binding domain of NEMO is required for tumor necrosis factor alpha-induced NF-kappa B activity. Marienfeld RB; Palkowitsch L; Ghosh S Mol Cell Biol; 2006 Dec; 26(24):9209-19. PubMed ID: 17000764 [TBL] [Abstract][Full Text] [Related]
17. Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease. Zilberman-Rudenko J; Shawver LM; Wessel AW; Luo Y; Pelletier M; Tsai WL; Lee Y; Vonortas S; Cheng L; Ashwell JD; Orange JS; Siegel RM; Hanson EP Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1612-7. PubMed ID: 26802121 [TBL] [Abstract][Full Text] [Related]
18. Covalent modification of the NF-κB essential modulator (NEMO) by a chemical compound can regulate its ubiquitin binding properties in vitro. Hooper C; Jackson SS; Coughlin EE; Coon JJ; Miyamoto S J Biol Chem; 2014 Nov; 289(48):33161-74. PubMed ID: 25296760 [TBL] [Abstract][Full Text] [Related]
19. Mutation of nonessential cysteines shows that the NF-κB essential modulator forms a constitutive noncovalent dimer that binds IκB kinase-β with high affinity. Cote SM; Gilmore TD; Shaffer R; Weber U; Bollam R; Golden MS; Glover K; Herscovitch M; Ennis T; Allen KN; Whitty A Biochemistry; 2013 Dec; 52(51):9141-54. PubMed ID: 24266532 [TBL] [Abstract][Full Text] [Related]
20. Use of fluorescence spectroscopy for quantitative investigations of ubiquitin interactions with the ubiquitin-binding domains of NEMO. Dubosclard V; Fontan E; Agou F Methods Mol Biol; 2015; 1280():321-37. PubMed ID: 25736758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]